89bio.png
89bio to Participate in Upcoming Investor Conferences
03 mai 2022 08h00 HE | 89bio, Inc.
SAN FRANCISCO, May 03, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio.png
89bio to Host Key Opinion Leader Webinar on Severe Hypertriglyceridemia (SHTG)
26 avr. 2022 08h00 HE | 89bio, Inc.
SAN FRANCISCO, April 26, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89biologo.png
89bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
24 mars 2022 16h05 HE | 89bio, Inc.
– Reported positive topline results from cohort 7 in the Phase 1b/2a trial including data from new analyses demonstrating the promising therapeutic utility of pegozafermin for the treatment of NASH – ...
89bio.png
89bio Announces Appointment of E. Morrey Atkinson, Ph.D., to its Board of Directors
24 févr. 2022 08h00 HE | 89bio, Inc.
SAN FRANCISCO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio.png
89bio to Participate in the SVB Leerink 11ᵗʰ Annual Global Healthcare Conference
09 févr. 2022 08h00 HE | 89bio, Inc.
SAN FRANCISCO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio.png
89bio Reports Positive Topline Results from an Expansion Cohort of the Phase 1b/2a Trial of Pegozafermin (BIO89-100) for the Treatment of NASH
24 janv. 2022 16h05 HE | 89bio, Inc.
63% of patients achieved 2-point or greater improvement in NAS without worsening of fibrosis; clinically meaningful improvements on registration enabling endpoints of NASH resolution (32%) and...
89bio.png
89bio Presents New Data from Phase 1b/2a NASH Study Showing BIO89-100 Reduces Spleen Volume 
14 nov. 2021 18h30 HE | 89bio, Inc.
New sub-analysis presented at The Liver Meeting® 2021 shows treatment with BIO89-100 reduced spleen volume by an average of 11.8% in NASH patients Oral presentation was highlighted by the AASLD...
89bio.png
89bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update
11 nov. 2021 16h05 HE | 89bio, Inc.
SAN FRANCISCO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89biologo.png
89bio Announces Appointment of Kathy LaPorte to its Board of Directors
03 nov. 2021 08h00 HE | 89bio, Inc.
SAN FRANCISCO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89biologo.png
89bio to Present New Sub-Analysis from Phase 1b/2a NASH Study of BIO89-100 at AASLD’s The Liver Meeting 2021
25 oct. 2021 16h05 HE | 89bio, Inc.
SAN FRANCISCO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...